State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism
Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived...
Uložené v:
| Vydané v: | Thrombosis and haemostasis Ročník 122; číslo 8; s. 1279 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Germany
01.08.2022
|
| ISSN: | 2567-689X, 2567-689X |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)-the combination of low-dose anticoagulants with antiplatelet agents-to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens-mostly rivaroxaban and aspirin-in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis-and thus maximize safety-should be assessed in appropriate populations. |
|---|---|
| AbstractList | Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)-the combination of low-dose anticoagulants with antiplatelet agents-to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens-mostly rivaroxaban and aspirin-in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis-and thus maximize safety-should be assessed in appropriate populations.Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)-the combination of low-dose anticoagulants with antiplatelet agents-to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens-mostly rivaroxaban and aspirin-in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis-and thus maximize safety-should be assessed in appropriate populations. Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low-flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high-flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and comorbidities predisposing individuals with VTE to ATE, and vice versa, and have bolstered the strategy of dual-pathway inhibition (DPI)-the combination of low-dose anticoagulants with antiplatelet agents-to reduce thrombotic outcomes on both sides of the vasculature. Randomized clinical trials have evaluated the efficacy and safety of such regimens-mostly rivaroxaban and aspirin-in high-risk groups of patients, including those with recent acute or chronic coronary syndrome, as well as those with peripheral artery disease with or without revascularization. Studies of extended VTE prophylaxis in acutely ill medical patients have also contributed to the evidence evaluating DPI. The totality of available data supports the concept that DPI can reduce major and fatal thromboembolic outcomes, including stroke, myocardial infarction, VTE, and cardiovascular death in key patient cohorts, with acceptable risk of bleeding. Further data are needed to refine which patients derive the best net clinical benefit from such an approach. At the same time, other novel agents such as contact pathway inhibitors that reduce thrombin generation without affecting hemostasis-and thus maximize safety-should be assessed in appropriate populations. |
| Author | Weitz, Jeffrey I Koulas, Ioannis Goldin, Mark Spyropoulos, Alex C |
| Author_xml | – sequence: 1 givenname: Mark surname: Goldin fullname: Goldin, Mark organization: Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States – sequence: 2 givenname: Ioannis surname: Koulas fullname: Koulas, Ioannis organization: Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, United States – sequence: 3 givenname: Jeffrey I surname: Weitz fullname: Weitz, Jeffrey I organization: Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada – sequence: 4 givenname: Alex C surname: Spyropoulos fullname: Spyropoulos, Alex C organization: Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35189662$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAQhoOs6Lp68i45eonmo0lbb8v6tbCi6CreSppMaaBN1jZ12X9vwRU8DDOH5x0e3hM08cEDQueMXjEq5bUmLE0zwmgmDtCUS5USleWfk3_3EToWkmW5UnyKzFvUEUioSKyBzLuIn5x3-BW-HWxv8O2gG_KiY73VO7z0tStddMHjGEbEDgbwGIHO6QZrb_EH-DD0eF13oS0DjNO4vj1Fh5Vuejjb7xl6v79bLx7J6vlhuZiviBE5jUTmVOSWMwMSDBXCmIRaSKU10lSJzSlXSaVMXpnEcGFHf2MryYQGkJUsSz5Dl79_N134GqCPRet6A02jPYxaBVeCZUqJXIzoxR4dyhZsselcq7td8VcM_wHBcGRg |
| CitedBy_id | crossref_primary_10_1002_adhm_202404960 crossref_primary_10_3390_jcdd10110461 crossref_primary_10_1055_a_2641_6568 crossref_primary_10_2174_1381612829666230830105750 crossref_primary_10_1016_j_jacadv_2023_100597 crossref_primary_10_1161_CIRCULATIONAHA_122_061987 crossref_primary_10_1016_j_jacadv_2023_100555 crossref_primary_10_1002_smll_202205260 crossref_primary_10_1055_a_2191_7627 crossref_primary_10_1093_ajhp_zxae182 crossref_primary_10_1038_s41416_022_01968_3 crossref_primary_10_1097_MAT_0000000000001892 |
| ContentType | Journal Article |
| Copyright | Thieme. All rights reserved. |
| Copyright_xml | – notice: Thieme. All rights reserved. |
| DBID | NPM 7X8 |
| DOI | 10.1055/a-1778-1083 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2567-689X |
| ExternalDocumentID | 35189662 |
| Genre | Journal Article |
| GroupedDBID | NPM 7X8 |
| ID | FETCH-LOGICAL-c390t-59039d21ce5ec033cc40de75dc5cf4d90264f6c9fc4c23d966cdf513aee5f5bb2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 14 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000846505100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2567-689X |
| IngestDate | Thu Jul 10 22:11:44 EDT 2025 Thu Jan 02 22:54:49 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | Thieme. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c390t-59039d21ce5ec033cc40de75dc5cf4d90264f6c9fc4c23d966cdf513aee5f5bb2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 35189662 |
| PQID | 2631866393 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2631866393 pubmed_primary_35189662 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationTitleAlternate | Thromb Haemost |
| PublicationYear | 2022 |
| Score | 2.4640925 |
| SecondaryResourceType | review_article |
| Snippet | Venous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1279 |
| Title | State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35189662 https://www.proquest.com/docview/2631866393 |
| Volume | 122 |
| WOSCitedRecordID | wos000846505100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-Dl584PtFBK_BNo-28SLiAz247EFlb0sySbDgtuquiv_eSbbiSRA8tJemaZjMpN-XmcwQcsQLB9z4knlhkaAUOBfGK2Daybw0trRShlRsouz1qsFA97sNt3EXVvm9JqaF2rUQ98iPeSFibjahxenzC4tVo6J3tSuhMUvmBUKZaJjlIBWhU2j_RaUH3ZG8TKljw_IyUqYspgj8DU6m38rV8n8HtEKWOkBJz6YasEpmfLNGIGFI1gaG-I7hM3pbNzWdOgJO6MWbeWJ9xH4f5pPeNI-1TYFbdNJiE4eTHbtLqklN4-hDyuNK7x5f25FtPV5P9Xi0Tu6vLu_Or1lXToGB0NmEKZ0J7XgOXnnIhACQmfOlcqAgSKeRjclQgA4ggQuHPAhcULkw3qugrOUbZK5pG79FaF7ZQuecg7HIXzSyaBUqjf1IaU2osm1y-C2zIapr9EGYxuNQhz9S2yabU8EPn6d5NYZC5RV-le_84e1dssjjQYQUirdH5gMaq98nC_A-qcevB0kP8N7r334BzWfAJg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=State-of-the-Art+Mini+Review%3A+Dual-Pathway+Inhibition+to+Reduce+Arterial+and+Venous+Thromboembolism&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Goldin%2C+Mark&rft.au=Koulas%2C+Ioannis&rft.au=Weitz%2C+Jeffrey+I&rft.au=Spyropoulos%2C+Alex+C&rft.date=2022-08-01&rft.issn=2567-689X&rft.eissn=2567-689X&rft.volume=122&rft.issue=8&rft.spage=1279&rft_id=info:doi/10.1055%2Fa-1778-1083&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2567-689X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2567-689X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2567-689X&client=summon |